Advertisement

PharmacoEconomics & Outcomes News

, Volume 840, Issue 1, pp 5–5 | Cite as

Baseline testing for resistance not cost effective if DAA costs high

Clinical study
  • 5 Downloads

Reference

  1. Fawsitt CG, et al. Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value in Health : 24 Oct 2019. Available from: URL: https://doi.org/10.1016/j.jval.2019.08.012

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations